Orticumab (Anti-oxLDL), 1mg

Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.